Autologous stem cell transplantation for malignant lymphomas

Bone Marrow Transplant. 1998 Dec:22 Suppl 4:S104-6.

Abstract

From December 1995 to April 1998, 20 consecutive adult patients suffering from chemosensitive relapse of Hodgkin's or non-Hodgkin lymphoma (11 Hodgkin, 9 non-Hodgkin Lymphoma) received autologous stem cell transplantation. The median follow up period is 15 months (range 6-28). The overall survival is 18/20 (90 %), the event free survival is 13/20 (65%). None of the patients died of transplant related cause.

MeSH terms

  • Adult
  • Disease-Free Survival
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease / therapy*
  • Humans
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Middle Aged
  • Transplantation, Autologous
  • Treatment Outcome